Iterum Therapeutics Confirms Nasdaq Delisting and Ceases SEC Filings Following Winding-Up Petition

summarizeSummary

Iterum Therapeutics plc announced its shares will be delisted from Nasdaq on April 1, 2026, and it will cease all SEC filings, confirming the final stages of its winding-up process.

check_boxKey Events

• Nasdaq Delisting Confirmed

  The company withdrew its appeal against Nasdaq's delisting determination, leading to the suspension of trading on April 1, 2026, and removal from the exchange.

• Cessation of SEC Filings

  Iterum Therapeutics announced it will no longer file reports with the SEC, including its 2025 Annual Report on Form 10-K, due to its winding-up process and limited cash.

• Follows Winding-Up Petition

  This delisting and cessation of filings are direct consequences of the company's petition to wind up in Ireland, as disclosed on March 27, 2026.

auto_awesomeAnalysis

This 8-K filing provides critical updates following the company's previously announced petition to wind up. The withdrawal of its appeal against Nasdaq's delisting determination confirms that trading of its ordinary shares will be suspended on April 1, 2026, effectively ending its public listing. Furthermore, the company explicitly states it will cease all future SEC filings, including its Annual Report on Form 10-K, due to limited cash and the ongoing winding-up process. This marks the definitive end of Iterum Therapeutics as a publicly traded and reporting entity, solidifying the complete loss of liquidity for shareholders on Nasdaq.